Haematologica

Article	Citations
Bence Jones Island in Shepherd Bay, Nunavut: a little known tribute to the legendary physician and chemist’s “thé de voyage”	135
Epigenetic dysregulation of eukaryotic initiation factor 3 subunit E (eIF3E) by lysine methyltransferase REIIBP confers a pro-inflammatory phenotype in t(4;14) myeloma	112
Genome-wide assessment of genetic risk loci for childhood acute lymphoblastic leukemia in Japanese patients	101
Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation	97
The first human acute myeloid leukemia genome ever fully sequenced	90
CD47 expression in acute myeloid leukemia varies according to genotype	73
BCL2 inhibition in adult acute lymphoblastic leukemia: ready for primetime?	64
Intra-marrow delivery of human interleukin-6-loaded biodegradable microspheres promotes growth of patient-derived multiple myeloma cells in mice	63
Investigating the influence of germline <i>ATM</i> variants in chronic lymphocytic leukemia on cancer vulnerability	60
Impact of soluble thrombomodulin and activated protein C on dynamic hemostatic function in trauma: a focus on thrombin generation and clot lysis	59
Oncogenic TYK2 P760L kinase is effectively targeted by combinatorial TYK2, mTOR and CDK4/6 kinase blockade	57
Acute myeloid leukemia at first relapse: approaching the precipice	53
Asciminib in chronic myeloid leukemia: a STAMP for expedited delivery?	53
Soluble SLAMF7 is generated by alternative splicing in multiple myeloma cells	52
Hematopoietic cell transplantation soon after first relapse in acute myeloid leukemia – the CONS	51
Clonal plasma cell features in light-chain amyloidosis are associated with depth and timing of cardiac response independent of hematologic response	49
Potassium/sodium cation carriers robustly up-regulate CD20 antigen by targeting MYC, and synergize with anti-CD20 immunotherapies to eliminate malignant B cells	47
Specific inhibition of the transporter MRP4/ABCC4 affects multiple signaling pathways and thrombus formation in human platelets	47
Venetoclax combined with escalating doses of homoharringtonine, low-dose cytarabine, and granulocyte colony-stimulating factor demonstrates feasibility and tolerability for remission induction in pedi	47
Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection	47
Salvage radiotherapy in relapsed/refractory large B-cell lymphoma after failure of CAR T-cell therapy	45
Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of <i>TP53</i> mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA group.	45
Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma after frontline DA-EPOCH-R	45
Genetic risk classification in acute myeloid leukemia patients treated with hematopoietic cell transplantation and post-transplant cyclophosphamide	43
Recognition, prevention, and management of adverse events associated with asparaginase / pegaspargase treatment of acute lymphoblastic leukemia in adults: consensus of an expert panel	40

“ASXL1”-erating inflammation and bone marrow fibrosis in myeloproliferative neoplasms	40
Infection risk in 158 patients with relapsed/refractory multiple myeloma treated with bispecific antibodies: a single-center experience	40
Teclistamab in relapsed refractory multiple myeloma: a multi-institutional real-world study from the French early access program	38
Asparaginase-associated hyperammonemia	38
Targeting glutaminase is therapeutically effective in ibrutinib-resistant mantle cell lymphoma	38
An unusual case of thalassemia intermedia with inheritable complex repeats detected by single-molecule optical mapping	38
Full <I>versus</i> prophylactic-intermediate doses of anticoagulants in COVID-19: a meta-analysis	37
PHF6 interacts with the LMO2 complex in T-cell acute lymphoblastic leukemia	37
Asparaginase dosing for acute lymphoblastic leukemia: more questions than answers	37
Artificial intelligence-based quantitative bone marrow pathology analysis for myeloproliferative neoplasms	37
Next-generation strategies to improve safety and efficacy of adeno-associated virus-based gene therapy for hemophilia: lessons from clinical trials in other gene therapies	37
LILRB4 represents a promising target for immunotherapy by dual targeting tumor cells and myeloid-derived suppressive cells in multiple myeloma	36
Comprehensive characterization of human bone marrow microenvironment shows age-related changes	36
Clinical impact of clonal hematopoiesis in hematopoietic cell transplantation: a review, metaanalysis, and call to action	35
Tocilizumab administration in cytokine release syndrome is associated with hypofibrinogenemia after chimeric antigen receptor T-cell therapy for hematologic malignancies	34
Acute lymphoblastic leukemia cells are able to infiltrate the brain subventricular zone stem cell niche and impair neurogenesis	34
A novel BCMA CAR-T-cell therapy with optimized human scFv for treatment of relapsed/refractory multiple myeloma: results from phase I clinical trials	33
A phase I study of the fully human, fragment crystallizable-engineered, anti-CD-33 monoclonal antibody BI 836858 in patients with previously-treated acute myeloid leukemia	33
Prognostic relevance of variant allelic frequency for treatment outcomes in patients with acute myeloid leukemia: a study by the Spanish PETHEMA registry	32
Clonal hematopoiesis by DNMT3A mutations as a common finding in idiopathic splanchnic vein thrombosis	32
The polymerase chain reaction, so simple, so clever: the discovery that made minimal residual disease come true	32
Prehistory of chronic lymphocytic leukemia: clues from the B-cell receptor	32
SH2 domain-containing inositol 5-phosphatases support the survival of Burkitt lymphoma cells by promoting energy metabolism	32
Running chromosome analysis in leukemia or not, upfront or later?	32
First-line MAPK inhibition in pediatric histiocytosis: are we ready?	32
Emergence of <i>TP53</i> mutation during lenalidomide therapy of myelodysplastic syndrome with del(5q) and its subsequent disappearance following salvage therapy with decitabine	31
Autologous-allogeneic versus autologous tandem stem cell transplantation and maintenance therapy with thalidomide for multiple myeloma patients over 60 years of age: a prospective phase II study	30
Kinetics matter: prognostic implications of early bone marrow assessment in acute myeloid leukemia	30
New bullets in the fight against cancer	30
MAPK-kinase mutations and aortic lesions are associated with distribution of circulating monocytes in histiocytosis	29
Myeloid/lymphoid neoplasms associated with eosinophilia and rearrangements of <i>PCM1::JAK2</i> with erythroblastic sarcoma: a case report and literature review	29
Blinatumomab is associated with better post-transplant outcome than chemotherapy in children with high-risk first-relapse B-cell acute lymphoblastic leukemia irrespective of the conditioning regimen	29
Chronic lymphocytic leukemia and associated chronic lung diseases	29
TIGIT: an immune checkpoint beyond T cells in chronic lymphocytic leukemia	28
Impact of central nervous system involvement in adult patients with Philadelphia-negative acute lymphoblastic leukemia: a GRAALL-2005 study	28
A third anti-SARS-CoV-2 mRNA dose does not overcome the pejorative impact of anti-CD20 therapy and/or low immunoglobulin levels in patients with lymphoma or chronic lymphocytic leukemia	28
Extracranial internal carotid artery and cerebral infarction in paediatric sickle cell patients	28
Epstein-Barr Virus and immune status imprint the immunogenomics of non-Hodgkin lymphomas occurring in immune-suppressed environments	27
Acute pro-B-cell lymphoblastic leukemia evolving from myelodysplastic neoplasm post cytotoxic therapy: a case report	27
Hematologic dysfunction and myeloid neoplasm risk in patients treated with lutetium-177 prostate specific antigen membrane therapy	27
In-depth characterization of intratumoral heterogeneity in refractory B-cell non-Hodgkin lymphoma through the lens of a Research Autopsy Program	27
Monocyte response to SARS-CoV-2 protein ORF8 is associated with severe COVID-19 infection in patients with chronic lymphocytic leukemia	27
In-depth cytogenetic and immunohistochemical analysis in a real world cohort - reconsidering the role of primary and secondary aberrations in multiple myeloma	26
Safe platelet count for lumbar puncture: are we being overcautious?	26
Mutations in the <i>RACGAP1</i> gene cause autosomal recessive congenital dyserythropoietic anemia type III	25
Advocating prudent D-dimer testing: constructive perspectives and comments on ‘How we manage a high D-dimer’	25
Daratumumab for treatment-refractory acquired idiopathic pure red cell aplasia	25
COVID-19 vaccine-induced adverse events predict immunogenicity among recipients of allogeneic hematopoietic stem cell transplantation	25
Molecular measurable residual disease by immunoglobulin gene rearrangements on circulating tumor DNA predicts outcome in diffuse large B-cell lymphoma	25
Mechanical unloading aggravates bone destruction and tumor expansion in myeloma	25

Dexamethasone added to induction and post-remission therapy in older patients with newly diagnosed acute myeloid leukemia: a multicenter, phase II trial (DEXAML-02)	25
<i>Ex vivo</i> venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia	25
Extended exposure to low doses of azacitidine induces differentiation of leukemic stem cells through activation of myeloperoxidase	24
Rituximab in addition to LMB-based chemotherapy regimen in children and adolescents with primary mediastinal large B-cell lymphoma: results of the French LMB2001 prospective study	24
Increased visceral fat distribution and body composition impact cytokine release syndrome onset and severity after CD19 chimeric antigen receptor T-cell therapy in advanced B-cell malignancies	23
Olverembatinib in accelerated-phase chronic myeloid leukemia: efficacy and safety evaluation	23
Cytomegalovirus Triplex vaccine in pediatric hematopoietic stem cell transplant patients at high risk for cytomegalovirus complications: evaluation of vaccine safety, immunogenicity and impact on vire	23
Gut microbiome alterations at acute myeloid leukemia diagnosis are associated with muscle weakness and anorexia	23
LP-118 is a novel B-cell lymphoma 2 / extra-large inhibitor that demonstrates efficacy in models of venetoclaxresistant chronic lymphocytic leukemia	23
Superior outcomes and high-risk features with carfilzomib, lenalidomide, and dexamethasone combination therapy for patients with relapsed and refractory multiple myeloma: Results of the multicenter KM	23
Myeloid lineage switch following CD7-targeted chimeric antigen receptor T-cell therapy in relapsed/refractory T-cell acute lymphoblastic leukemia	23
Predictors of SARS-CoV-2 Omicron breakthrough infection after receipt of AZD7442 (tixagevimab-cilgavimab) for pre-exposure prophylaxis among hematologic malignancy patients	22
IgM monoclonal gammopathies of clinical significance: diagnosis and management	22
How we changed our approach to venous thromboembolism	22
Lenalidomide maintenance after bortezomib, thalidomide and dexamethasone (VTD) induction and autologous stem cell transplantation: an Italian real-life study of 602 patients	22
Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trial	22
The lymph node transcriptome of unicentric and idiopathic multicentric Castleman disease	22
Identification of a clinicopathologic prognostic index for newly diagnosed large B-cell lymphoma patients treated with R-CHOP	22
Aspirin is a life-saving drug for patients with acute myocardial infarction	22
Treatment of lower-risk myelodysplastic syndromes	22
Resistance to PI3Kδ inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis	22
Altered mesenchymal and endothelial subsets in interstitial bone marrow and focal lesions in myeloma patients and SCID-hu mice	22
An investigation of germline variants of <i>HAVCR2</i> in subcutaneous panniculitis-like T-cell lymphoma and related lesions in a North American population	22
Clonal evolution from B-cell acute lymphoblastic leukemia with <i>BCR::ABL1</i> multilineage involvement to acute myeloid leukemia after multiple anti-CD19 chimeric antigen receptor T-cell	21
Landscape of immunoglobulin heavy chain γ gene class switch recombination in patients with adult T-cell leukemia–lymphoma	21
COVID-19 thromboembolism is reduced in ambulatory, but not hospitalized patients, following COVID-19 vaccination Short title: COVID-19 thromboembolism	21
Prior cancer and risk of monoclonal gammopathy of undetermined significance: a population-based study in Iceland and Sweden	21
Getting (T cells) ENGaged	21
Biosimilars in rare diseases: a focus on paroxysmal nocturnal hemoglobinuria	20
Teclistamab therapy for refractory type 1 cryoglobulinemia Teclistamab in type 1 cryoglobulinemia	20
A sheep in wolf's clothing? Wild-type P53 disguises as mutant to promote leukemogenesis	20
HBV infection in the era of T-cell engagers in multiple myeloma: unresolved challenges and unmet needs. Comment on: Hepatitis B virus reactivation following T-cell engager therapy in multiple myeloma	20
LSD1/KDM1A and GFI1B repress endothelial fate and induce hematopoietic fate in induced pluripotent stem cell-derived hemogenic endotheliums	20
αβT- and B-cell-depleted HLA-haploidentical hematopoietic stem cell transplantation in children with myelodysplastic syndromes	20
Hemostatic and protein C pathway dysfunction in the pathogenesis of experimental cerebral malaria	19
Anti-HLA class I IgG subclasses skew platelet activation mechanisms in transfusion refractoriness	19
“Bridegroom of blood”- A biblical reference to hemophilia?	19
von Hippel- Lindau syndrome-related congenital polycythemia and response to belzutifan	19
Reply to the Comment on: “Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA Registry”	19
Impact of letermovir on Cytomegalovirus-specific T-cells reconstitution after allogeneic hematopoietic stem cell transplantation in the post-transplant cyclophosphamide era	19
The French-American-British classification system for acute myeloid leukemia	19
LNK/<i>SH2B3</i> as a novel driver in juvenile myelomonocytic leukemia	19
Genomic analysis of venous thrombosis in children with acute lymphoblastic leukemia from diverse ancestries	19
Zanubrutinib, rituximab and lenalidomide induces deep and durable remission in TP53-mutated B-cell prolymphocytic leukemia: a case report and literature review	18
LDHAL6B is a novel prognostic marker and promotes disease progression in multiple myeloma	18
<i>Ex vivo</i> correction of severe coagulation Factor VII deficiency in patient-derived 3D liver organoids	18
Pirtobrutinib and venetoclax combination overcomes resistance to targeted and chimeric antigen receptor T-cell therapy in aggressive mantle cell lymphoma	18
More than a Lonca-shot: beating the odds in relapsed/refractory diffuse large B-cell lymphoma	18
A phase II trial of azacitidine with ipilimumab, nivolumab, or ipilimumab and nivolumab in previously untreated myelodysplastic syndrome	18
Duality of Nrf2 in iron-overload cardiomyopathy	18
Long-term outcomes and renal responses following autologous hematopoietic stem cell transplantation for light chain deposition disease: a retrospective study on behalf of the Chronic Malignancies Work	18
The relative importance of platelet integrins in hemostasis, thrombosis and beyond	17
The International Prognostic Index: still relevant 30 years later	17
Age-specific mutation profiles and their prognostic implications in pediatric <i>KMT2A</i>-rearranged acute myeloid leukemia	17
CNS infiltration by zamtocabtagene autoleucel tandem CD20/CD19 CAR T cells leading to complete remission in a patient with primary CNS lymphoma	17
CAR T-cell treatment of high-risk multiple myeloma: will there be a cure?	17
Genomics improves risk stratifi cation of adults with T-cell acute lymphoblastic leukemia enrolled in measurable residual disease-oriented trials	17
STAT5 does not drive steroid resistance in T-cell acute lymphoblastic leukemia despite the activation of <i>BCL2</i> and <i>BCLXL</i> following glucocorticoid treatment	17
More on the pathogenesis of thrombotic thrombocytopenic purpura. Comment on “Acquired thrombotic thrombocytopenic purpura without detectable anti-ADAMTS13 antibodies: a possible underlying autoimmune	16
Outcomes of children and young adults with B-cell acute lymphoblastic leukemia given blinatumomab as last consolidation treatment before allogeneic hematopoietic stem cell transplantation	16
Understanding pharmacological complement inhibition in paroxysmal nocturnal hemoglobinuria	16
Leon's helmet	16
A report from the Leukemia Electronic Abstraction of Records Network on risk of hepatotoxicity during pediatric acute lymphoblastic leukemia treatment	16
Type I interferons: leukemia's old foe in the limelight again	16
Harnessing the cytotoxic granule exocytosis to augment the efficacy of T-cell-engaging bispecific antibody therapy.	16
Elucidation of molecular basis of osteolytic bone lesions in advanced multiple myeloma	16
Monomorphic epitheliotropic intestinal T-cell lymphoma comprises morphologic and genomic heterogeneity impacting outcome	16
Entities <i>versus</i> diseases: Myers <i>et al</i>. propose distinct aspects of adult T-cell lymphoma / leukemia.	16
Introduction. Immunotherapy for childhood malignancies: the future is now	16
Functional, biochemical, molecular and clinical characterization of antithrombin c.1157T>C (p.Ile386Thr), a recurrent Polish variant with a founder effect	15
Dissecting CD47 expression in lymphoid neoplasms to inform precision immunotherapy with anti-CD47 phagocytic checkpoint blockade	15
Safety and efficacy of flumatinib as later-line therapy in patients with chronic myeloid leukemia	15
Defibrotide improves COVID-19-related acute respiratory distress syndrome in myeloma patients after chimeric antigen receptor T-cell treatment without compromising virus-specific and anti-myeloma T-ce	15
Single-cell analysis of the T-cell receptor repertoire in untreated myeloma patients suggests potential myeloma-reactive CD8+ T-cells are shared between blood and marrow	15
Metabolic profile evolution in relapsed/refractory B-cell non-Hodgkin lymphoma patients treated with CD19 chimeric antigen receptor T-cell therapy and implications in clinical outcome	15
Follicular lymphoma grade 3B: low grade, high grade or should we skip the grade?	15
Acquired thrombotic thrombocytopenic purpura without detectable anti-ADAMTS13 antibodies: a possible underlying autoimmune mechanism.	15
Polytypic B cells, monotypic/monoclonal B-cell proliferations, and neoplastic T cells diverge from <i>TET2</i>-/<i>DNMT3A</i>-mutant clonal hematopoiesis in follicular helper T	15
Cancer-related thrombosis: impact of biological sex on the risk of rethrombosis and bleeding	15
Amyloidogenic light chains impair plasma cell survival	15

CCRL2 and who? An important driver in <i>TP53-</i>mutant myeloid leukemias	15
<i>Erratum</i> to: Prevalence and mortality trends of hemoglobinopathies in Italy: a nationwide study	15
Phase I study of the Syk inhibitor sovleplenib in relapsed or refractory mature B-cell tumors	15
Home time among older adults with acute myeloid leukemia by therapy intensity	15
Diagnostic challenges and proposed classification of myeloid neoplasms with overlapping features of thrombocytosis, ring sideroblasts and concurrent del(5q) and <i>SF3B1</i> mutations	15
Universal germline genetic testing in patients with hematologic malignancies using DNA isolated from nail clippings	15
Adenosine signaling inhibits erythropoiesis and promotes myeloid differentiation	15
Delving the depths of measurable residual disease negativity in acute myeloid leukemia	15
The E3 ligase TRIM31 regulates hematopoietic stem cell homeostasis and MLL-AF9 leukemia	15
An extensive database analysis demonstrates significant increase in platelet quantity in unselected hospitalized patients following treatment with oseltamivir	15
Acute leukemia of ambiguous lineage: the known and the uncertain	14
Umbilical cord blood T cells can be isolated and enriched by CD62L selection for use in 'off the shelf' chimeric antigen receptor T-cell therapies to widen transplant options	14
Racial differences in the proportion of myeloma cases attributable to excess body weight and diabetes mellitus in the United States	14
Pharmacologic targeting of the p62 ZZ domain enhances both anti-tumor and bone-anabolic effects of bortezomib in multiple myeloma	14
Dissociated humoral and cellular immune responses after a three-dose schema of BNT162b2 vaccine in patients receiving anti-CD20 monoclonal antibody maintenance treatment for B-cell lymphomas	14
Sex differences in progression of kidney disease in sickle cell disease	14
Modern, real-world patterns of care and clinical outcomes among patients with newly diagnosed diffuse large B-cell lymphoma with or without double/triple-hit status in the United States	14
<i>BRCA1/2</i> mutations and <i>de novo</i> hematologic malignancies: true, true and not clearly related	14
Prognostic value of early positron emission tomography in patients with large B-cell lymphoma treated with anti-CD19 chimeric antigen receptor T-cell therapy	14
PTPN11 mutations define a rare but highly adverse subset of myelodysplastic syndromes	14
Association of <i>NUDT15</i> gene polymorphism with adverse reaction, treatment efficacy, and dose of 6-mercaptopurine in patients with acute lymphoblastic leukemia: a systematic review an	14
The effects of cardio-selective β blockade on diastolic dysfunction in children with sickle cell disease	14
Efficacy of intravenous high-dose methotrexate in preventing relapse to the central nervous system in R-CHOP(-like)-treated, high-risk, diffuse large B-cell lymphoma patients and its effect on mortali	14
Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma	14
Treatment patterns and outcomes in relapsed/refractory follicular lymphoma: results from the international SCHOLAR-5 study	14
Somatic genetic alterations predict hematological progression in GATA2 deficiency	14
Toward chemotherapy-reduced cure for TCF3::HLF B-cell acute lymphoblastic leukemia using CD-19-directed immunotherapy	14
Syndromes predisposing to leukemia are a major cause of inherited cytopenias in children	14
CXCL8 and its cognate receptors CXCR1/CXCR2 in primary myelofibrosis	14
Teclistamab <i>versus</i> B-cell maturation antigen-targeting chimeric antigen receptor T-cell therapy in multiple myeloma: a comparative effectiveness analysis	14
Profiling the activity of the para-caspase MALT1 in B-cell acute lymphoblastic leukemia for potential targeted therapeutic application	14
Response to the Comment: “Advocating prudent D-dimer testing: constructive perspectives and comments on “How we manage a high D-dimer”	14
Deep immunophenotypic dissection and clinical impact of T cells in the follicular lymphoma microenvironment	13
Ethnicity in systemic AL amyloidosis may impact risk stratification	13
Acute myeloid leukemia with mast cell differentiation is characterized by interstitial mast cells, complex karyotype, <i>TP53</i> alterations and poor prognosis	13
Effects of corticosteroids in patients with sickle cell disease and acute complications: a systematic review and meta-analysis	13
Outcomes and genetic dynamics of acute myeloid leukemia at first relapse	13
Treatment-related mutagenic processes in acute lymphoblastic leukemia	13
Phosphatase, Mg<sup>2+</sup>/Mn<sup>2+</sup> dependent 1B regulates the hematopoietic stem cells homeostasis via the Wnt/β-catenin signaling	13
Enhancement of PRMT6 binding to a novel germline <i>GATA1</i> mutation associated with congenital anemia	13
Evaluation of the <i>ATM</i> L2307F germline variant in 121 Italian pedigrees with familial myeloproliferative neoplasms	13
Mucosal-associated invariant T cells are functionally impaired in pediatric and young adult patients following allogeneic hematopoietic stem cell transplantation and their recovery correlates with cli	13
Randomized trial of anti-thymocyte globulin plus low-dose post-transplant cyclophosphamide to prevent graft-versus-host disease in haploidentical transplantation	13
MD-ALL: an integrative platform for molecular diagnosis of B-acute lymphoblastic leukemia	13
Marginal zone lymphoma with anti-factor H IgM and atypical hemolytic uremic syndrome successfully treated with odronextamab	13
Do it once, but do it right	13
Artificial intelligence-based Myelodysplastic Syndromes Score, 2022 classifications, and the Molecular International Prognostic Scoring System: a perfect match	13
The double-edged sword of adenosine	13
Systemic diffuse large B-cell lymphoma involving the central nervous system have high rates of defective antigen presentation and immune surveillance	13
RNA helicase DHX15 exemplifies a unique dependency in acute leukemia	13
Metabolic signatures of cardiorenal dysfunction in plasma from sickle cell patients as a function of therapeutic transfusion and hydroxyurea treatment	13
Arkadia: a new player in hematopoietic stem and progenitor cell development	13
Detection of <I>ABL1</I> kinase domain mutations in therapy-naïve <I>BCR-ABL1</I>-positive acute lymphoblastic leukemia	12
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i>versus</i> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE t	12
Immunosuppression with post-transplant cyclophosphamide for allogeneic hematopoietic cell transplantation	12
<i>Erratum</i> to: Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual di	12
Impact of minimal residual disease on the outcome of hematopoietic stem cell transplantation for childhood acute lymphoblastic leukemia within the FORUM Trial	12
Expanding treatment options by selectively targeting the cytokine storm with ruxolitinib in primary hemophagocytic lymphohistiocytosis	12
Factors associated with left ventricular hypertrophy in children with sickle cell disease: results from the DISPLACE study	12
Treatment of drug-induced immune thrombocytopenias	12
Global estimation of the bleeding episodes treatable with desmopressin in von Willebrand disease and hemophilia A	12
Molecular responses in decitabine- and decitabine/venetoclax-treated patients with acute myeloid leukemia and myelodysplastic syndromes	12
B-cell precursor acute lymphoblastic leukemia elicits an interferon-α/βresponse in bone marrow-derived mesenchymal stroma	12
Clinical and molecular features of <i>CBL</i>-mutated juvenile myelomonocytic leukemia	12
Depletion of the RNA binding protein QKI and circular RNA dysregulation in T-cell acute lymphoblastic leukemia	12
Isatuximab-pomalidomide-dexamethasone <i>versus</i> pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis	12
Cytomegalovirus reactivation after CD19 CAR T-cell therapy is clinically significant	12
The immunophenotypic and genetic characterization of pediatric T -L ymphoblastic leukemia with a mature immunophenotype	12
Concurrent peripheral T-cell lymphoma and T-cell lymphoblastic leukemia/lymphoma with identical <i>STIL</i>::<i>TAL1</i> fusion events	12
General condition and comorbidity of long-term survivors of adult acute lymphoblastic leukemia	12
Hematopoietic cell transplants for acute leukemias	12
Evolution in treatment of acute promyelocytic leukemia: a major victory	11
Prognostic stratification in venetoclax-based acute myeloid leukemia treatments: the molecular prognostic risk signature tested in a real-world setting	11
HLA-C*04:09N is expressed at the cell surface and triggers peptide-specific T-cell activation	11
Nandrolone decanoate: new therapeutic option for telomeropathies?	11
Outstanding outcomes in infants with <i>KMT2A</i>-germline acute lymphoblastic leukemia treated with chemotherapy alone: results of the Children’s Oncology Group AALL0631 trial	11
Clinical and molecular response of acute myeloid leukemia harboring non-canonical <i>FLT3</i> N676K driver mutations to contemporary FLT3 inhibitors	11
Intricacies of GATA-ca, continued	11
Relapsed acute lymphoblastic leukemia: back to the drawing board	11
Comprehensive genomic analysis of refractory multiple myeloma reveals a complex mutational landscape associated with drug resistance and novel therapeutic vulnerabilities	11
A phase IIb study of selinexor in combination with daratumumab in patients with daratumumab-refractory multiple myeloma	11
Expanding the bacterial origins of nodular lymphocyte-predominant Hodgkin lymphoma	11
Time without transfusion reliance: a novel patient-centric metric for new therapies in myelodysplastic syndromes	11
<i>ASXL1</i> mutations accelerate bone marrow fibrosis via EGR1-TNFA axis-mediated neoplastic fibrocyte generation in myeloproliferative neoplasms	11
Revaccination with pneumococcal conjugate vaccine five years after primary immunization improves immunity in patients with chronic lymphocytic leukemia	11
A phase II randomized, placebo-controlled, multicenter trial to evaluate the efficacy of cytomegalovirus PepVax vaccine in preventing cytomegalovirus reactivation and disease after allogeneic hematopo	11
One CHiP to rule them all? Mechanistic insight into carfilzomib-induced lung injury with neutrophil extracellular trap formation following cellular immunotherapy	11
Prevention, diagnosis and management of myeloproliferative neoplasms: an introduction to a review series	11
Contribution of copy number to improve risk stratification of adult T-cell acute lymphoblastic leukemia patients enrolled in measurable residual disease-oriented trials	11
Beyond adenosine triphosphate: unveiling the pleiotropic effects of pyruvate kinase activation in sickle cell anemia	11
A case series of patients with β-thalassemia trait and iron overload: from multifactorial hepcidin suppression to treatment with mini-phlebotomies	11
Profound and sustained response with next-generation ALK inhibitors in patients with relapsed or progressive ALK-positive anaplastic large cell lymphoma with central nervous system involvement	11
Sorting nexin 24 is required for α-granule biogenesis and cargo delivery in megakaryocytes	11
Differential transcriptional control of hematopoiesis in congenital and cycling neutropenia patients harboring <i>ELANE</i> mutations	11
Anatomy of a crime: how IL7R and NRAS join forces to drive T-cell acute lymphoblastic leukemia	11